(Approval lapsed 6/01/2020) Intuniv 1mg Extended Release tablets

INTUNIV is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). INTUNIV must be used as part of a comprehensive ADHD management programme, typically including psychological, educational and social measures.